Recommendations for the prevention and treatment of hepatitis B and C infection in patients on the waiting list for liver transplantation and in liver transplant recipients

1. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for testing, managing, and treating hepatitis C virus infection. AASLD/IDSA HCV guidance panel. Clin Infect Dis. 2018;67(10):1477–1492. PMID: 30215672 https://doi.org/10.1002/hep.27950

2. Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. European association for the study of the liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511. PMID: 29650333 https://doi.org/10.1016/j.jhep.2018.03.026

3. Omata M, Kanda T, Wei L, Yu M-L, Chuang W-L, Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10(5):702–726. PMID: 27130427 https://doi.org/10.1007/s12072-016-9717-6

4. Terrault NA, Lok ASF, McMahon BJ, Kyong-Mi C, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. PMID: 29405329 https://doi.org/10.1002/hep.29800

5. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. AsianPacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. PMID: 26563120 https://doi.org/10.1007/s12072-015-9675-4

6. Lampertico P, Agarwal K, Berg T, Buti M, Janssen H LA, Papatheodoridis G, et al. European association for the study of the liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. PMID: 28427875 https://doi.org/10.1016/j.jhep.2017.03.021

7. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org/full-report-view [Accessed July 23, 2020].

8. ZuSiederdissen CH, Maasoumy B, Marra F, Deterding K, Port K, Manns MP, et al. Drug-Drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62(5):561–567. PMID: 26611779 https://doi.org/10.1093/cid/civ973

9. Сюткин В.Е., Бессонова Е.Н., Давыденко М.Н. Терапия возвратного гепатита C после трансплантации печени препаратами прямого противовирусного действия: опыт трёх российских центров. Эпидемиология и инфекционные болезни. 2018;23(1):4–14. Syutkin VE. Bessonova EN, Davydenko MN. Therapy of recurrent hepatitis C after transplantation of the liver with direct acting anti-hepatitis C virus drugs: experience of three Russian centers. Epidemiology and Infectious Diseases. 2018;23(1):4–14. https://dx.doi.org/10.18821/1560-9529-2018-23-1-4-14

10. Сюткин В.Е., Федин А.Б. Противовирусная терапия инфекции HCV в безинтерфероновую эру: лечить больных с декомпенсированным циррозом до трансплантации печени или с возвратной инфекцией трансплантата? Инфекционные болезни. 2017;15(1):48– 54. Syutkin VE, Fedin AB. Antiviral therapy for HCV infection in an interferon-free age: shall we treat patients with decompensated cirrhosis before liver transplantation or with recurrent infection of the transplant? Infectious Diseases. 2017;15(1):48–54. https://doi.org/10.20953/1729-9225-2017-1-48-54

11. Коробка В.Л., Пак Е.С., Пасечников В.Д., Кострыкин M.Ю. Развитие рекомпенсации у больных HCV-ассоциированным декомпенсированны циррозом печени после терапии современными препаратами прямого противовирусного действия. Доказательная гастроэнтерология. 2019;8(4–5):11– 21. Korobka VL, Pak ES, Pasechnikov VD, KostrykinMYu. Compensation of HCV-associated decompensated cirrhosis treated with modern direct-acting antiviral agents. Russian journal of Evidence-based gastroenterology. 2019;8(4– 5):11–21. https://doi.org/10.17116/dokgastro2019804-05111